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A role for MALT1 activity in Kaposi’s sarcoma-associated
herpes virus latency and growth of primary effusion lymphoma
L Bonsignore1, K Passelli1, C Pelzer1, M Perroud1, A Konrad2, M Thurau2, M Stürzl2, L Dai3,4, J Trillo-Tinoco5, L Del Valle5, Z Qin3,4
and M Thome1
Primary effusion lymphoma (PEL) is an incurable malignancy that develops in immunodeﬁcient patients as a consequence of latent
infection of B-cells with Kaposi’s sarcoma-associated herpes virus (KSHV). Malignant growth of KSHV-infected B cells requires the
activity of the transcription factor nuclear factor (NF)-κB, which controls maintenance of viral latency and suppression of the viral
lytic program. Here we show that the KSHV proteins K13 and K15 promote NF-κB activation via the protease mucosa-associated
lymphoid tissue lymphoma translocation protein-1 (MALT1), a key driver of NF-κB activation in lymphocytes. Inhibition of the
MALT1 protease activity induced a switch from the latent to the lytic stage of viral infection, and led to reduced growth and survival
of PEL cell lines in vitro and in a xenograft model. These results demonstrate a key role for the proteolytic activity of MALT1 in PEL,
and provide a rationale for the pharmacological targeting of MALT1 in PEL therapy.
Leukemia (2017) 31, 614–624; doi:10.1038/leu.2016.239
INTRODUCTION
Primary effusion lymphoma (PEL) is a rare B-cell malignancy that
originates from B cells latently infected with Kaposi’s sarcoma-
associated herpes virus (KSHV, also known as human herpes virus-8,
HHV8). PEL is almost exclusively observed in immunosuppressed
patients, such as organ transplant recipients and HIV-1-infected
patients.1 PEL is an aggressive and incurable malignancy, with a
median survival of o6 months under standard multi-agent
chemotherapy with cyclophosphamide, hydroxydaunorubicin,
oncovin and prednisolone (CHOP).1
As for other herpesviruses, KSHV can exhibit either a latent
(non-productive) or a lytic (productive) life cycle that are
characterized by distinct viral gene expression proﬁles.2 Cellular
oncogenesis by KSHV requires maintenance of the virus in the
latent stage, as productive infection leads to lysis and death of the
infected cells. Presently available anti-herpes virus drugs target
only the lytic stage of virus replication, therefore latently KSHV-
infected lymphoma cells are resistant to antiviral agents.3 A better
understanding of the molecular mechanism of KSHV-driven
oncogenesis is required to develop new therapeutic strategies,
which should combine agents promoting lytic KSHV reactivation
from latently infected cells with drugs that block the spreading of
the virus, in order to selectively kill PEL cells.4,5
Latent KSHV infection of lymphocytes is associated with
constitutive activation of the transcription factor nuclear factor
(NF)-κB, which actively promotes virus latency and represses lytic
replication in vitro.6–8 NF-κB activity is also critical for the growth
of KSHV-infected lymphoma cells in vivo, as growth of a
xenografted PEL is efﬁciently delayed by treatment of the animals
with Bay-11-7082, an irreversible inhibitor of NF-κB activation.9,10
Several KSHV gene products that promote NF-κB activation have
been identiﬁed. These include the anti-apoptotic viral FLIP protein
encoded by the viral open reading frame (ORF) K13,11 and ORF
K15 that is structurally and functionally homologous to the
NF-κB-inducing latency-associated membrane protein-2A of EBV.12–14
K13 has been proposed to largely account for the constitutive NF-κB
activation and expression of NF-κB target genes such as c-IAP1/2,
cFLIP-L and IL-6 in latently infected lymphocytes.15 A possible
contribution of K15 to NF-κB activation during viral latency is
supported by its reported expression in latently KSHV-infected B
cells,16 and the observation that K15 induces NF-κB target genes such
as c-IAP2, A20 and TRAF1 in primary human B cells when expressed in
the context of an EBV mutant expressing K15 instead of the latent
EBV gene latency-associated membrane protein-2A.13
Biochemical studies have revealed some insights into the
molecular mechanisms that control NF-κB activation by K13 and
K15. K13 is a cytoplasmic protein that promotes NF-κB activation
via its physical interaction with the IKK complex,17,18 which
phosphorylates the NF-κB inhibitor IκB to target it for proteasomal
degradation. K15-dependent NF-κB activation requires the
tyrosine residue 481 within the putative SH2-binding site YEEVL
in the K15 cytoplasmic domain,12 together with a stretch of
membrane-proximal amino acids that recruit the kinase NIK and
the IKK complex.19 It is likely that additional, yet undiscovered
mechanisms contribute to K13- and K15-dependent NF-κB
activation.
The paracaspase mucosa-associated lymphoid tissue lymphoma
translocation protein-1 (MALT1) is a Cys-dependent, Arg-speciﬁc
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protease that controls antigen receptor-induced NF-κB activation
in lymphocytes via both, its scaffold and protease activities.
As a scaffold, MALT1 promotes the activation of the IKK complex,
most likely via recruitment of the ubiquitin ligase TRAF6(ref. 20) and
the linear ubiquitination chain assembly complex.21,22 The
protease activity of MALT1 massively enhances the NF-κB
response by the cleavage of A20 and RelB, which negatively
regulate the canonical NF-κB pathway in lymphocytes.23,24
MALT1 was originally identiﬁed as a proto-oncogene in
B-cell lymphomas of the mucosa-associated lymphoid tissue, in
which MALT1 is constitutively activated as a result of chromoso-
mal translocations that lead to MALT1 overexpression or forma-
tion of an oncogenic apoptosis inhibitor protein-2-MALT1 fusion
protein.25 Naturally, MALT1 is activated upon antigenic triggering
of the B-cell receptor (BCR)/CD79 complex. This initiates a
signaling cascade that activates Bruton’s tyrosine kinase (BTK)
and induces the formation of the CBM signaling complex formed
by CARMA1 (also known as CARD11), BCL10 and MALT1, which is
required for MALT1 activation.26 Constitutive MALT1 activity is
observed in diffuse large B-cell lymphomas (DLBCL) of the
activated B-cell (ABC) subtype,27,28 which are characterized by
chronic BCR-BTK-CBM signaling.29 Recently, small molecule
inhibitors of MALT1 have been developed that efﬁciently inhibit
the growth of ABC DLBCL in xenograft models,30,31 but whether
MALT1 inhibition may also be effective against virally induced
tumors with constitutive NF-κB activation has not been explored.
Here, we have identiﬁed a key role for MALT1 downstream of
the viral NF-κB inducers K13 and K15 of KSHV, and demonstrated
that MALT1 activity is critical for viral latency and cellular growth
of PEL cells in vitro and in a xenograft model. These ﬁndings
suggest that therapeutic inhibition of MALT1 may be used as a
rational strategy to treat PEL by purging the reservoir of latently
infected cells driving this malignancy.
MATERIALS AND METHODS
Cell culture, cell treatment and reagents
HEK293T cells (a kind gift of the late Jürg Tschopp, UNIL, Lausanne,
Switzerland) and BCBL-1 cells (a kind gift of Pascal Meylan, CHUV,
Lausanne, Switzerland) were cultured in Dulbecco's Modiﬁed Eagle
Medium and in RPMI (Rosewell Park Memorial institute) 1640, respectively,
supplemented with 10% fetal bovine serum and antibiotics. The
lymphoma cell lines BC-3, BC-1 and BCP-1 (ATCC) and HBL-1 (a kind gift
of Louis Staudt, NCI, Bethesda, MD, USA) were cultured in RPMI 1640
supplemented with 20% fetal bovine serum and antibiotics. Lentivirally
transduced HEK293T, BCBL-1 and BC-3 cells were kept under puromycin
selection (1 μg/ml) at all times. All cell lines were regularly tested for
mycoplasma (using MycoAlert Mycoplasma Detection Kit, Lonza, Basel,
Switzerland). Thioridazine (Sigma-Aldrich, Buchs, Switzerland), staurospor-
ine (Sigma-Aldrich), and ibrutinib (Selleck Chemicals, Houston, TX, USA)
were diluted in phosphate-buffered saline (thioridazine) or dimethyl
sulfoxide (all others), and used to treat cells at indicated ﬁnal concentra-
tions. For KSHV reactivation assays, BCBL-1 and BC-3 cells were
resuspended in media containing thioridazine, incubated for 6 h, then
spun down and resuspended in fresh RPMI media. RNA was harvested 24 h
after onset of thioridazine treatment.
Quantitative Real Time PCR
Total RNA from BCBL-1 and BC-3 cells was extracted with TRIzol reagent
(Life Technologies, Thermo Fisher Scientiﬁc, Reinach, Switzerland) according to
manufacturer's instructions and complementary DNA was synthesized with a
High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Thermo
Fisher Scientiﬁc). SYBR Green ﬂuorescent reagent and LightCycler480
Real Time PCR System (Roche Diagnostics, Basel, Switzerland) were used for
quantitative RT-PCR. The relative amount of mRNA was calculated by the
comparative threshold cycle method with the housekeeping gene GAPDH
(forward: 5′-GAAGGTGAAGGTCGGAGT-3′, reverse: 5′-GAAGATGGTGATGGGA
TTTC-3′) as control. Primers for ORF57 (forward: 5′-TGGACATTATGAAGGGC
ATCC-3′, reverse: 5′-CGGGTTCGGACAATTGCT-3′) and gB (forward: 5′-TCGCCGC
ACCAATACCATA-3′, reverse: 5′-CCTGCGATCTACGTCGGG-3′)8 and for K8.1
(forward: 5′-TGGTGCTAGTAACCGTGTGCC-3′, reverse: 5′-TCTGCATTGTAGTGCG
CGTC-3′)32 have been previously described.
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Figure 1. MALT1 activity is required for survival of PEL cell lines. (a) Cell viability analysis of BJAB (GCB DLBCL), HBL-1 (ABC DLBCL), BC-3 and
BCBL-1 (PEL) cells treated with 3.125, 6.25, 12.5, 25 or 50 nM of the BTK inhibitor ibrutinib for 72 h, with the indicated concentrations of the
MALT1 inhibitor thioridazine for 48 h, or with staurosporine (STS) for 3 h. (b and c) Western blot analysis of the indicated cell lines to assess
expression of BTK (b), or MALT1, BCL10, CARMA1 and cleavage of BCL10 (c). Tubulin blot serves as a loading control. Data are means± s.d. of
duplicate (ibrutinib) or triplicate (all others) measurements (a) and representative of two independent experiments (a–c).
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KSHV reactivation assays
HEK293T cells (3 × 105 cells/well) were seeded in a six-well plate, and
infected 24 h later with rKSHV219,33 which expresses green or red
ﬂuorescent protein dependent on the latent or lytic viral state, respectively,
in the presence of 8 μg/ml polybrene (S2667, Sigma-Aldrich). On day 2,
cells were washed and on day 4, supernatant was harvested and used to
infect wild-type HEK293T cells, previously seeded at 1 × 105 cells/well in a
12-well plate. On day 7, HEK293T cells were harvested and analyzed by
ﬂow cytometry for green ﬂuorescent protein expression.
Cell viability assay
Cells (2.5×105/ml) were treated with indicated concentrations of thiorida-
zine, staurosporin, ibrutinib or vehicle alone (phosphate-buffered saline or
dimethyl sulfoxide) for 48, 3 and 72 h, respectively, and cell viability was
assessed using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS, Promega, Dübendorf, Switzerland, at
400 μg/ml) and phenazine methosulfate (PMS, Sigma-Aldrich, at 9 μg/ml),
according to the manufacturer's instructions. Reduction of MTS to formazan
was measured at 492 nm with Capture 96 Software (Basel, Switzerland) on a
LEDETECT 96 microplate spectrophotometer (Dynamica Scientiﬁc, Zürich,
Switzerland). Cell viability of ibrutinib-treated cells was assessed using WST-1
assay (Roche Diagnostics) following the manufacturer’s instructions.
Antibodies
Antibodies used for western blotting include anti-BTK (D3H5, Cell
Signaling Technology/Bioconcept, Allschwil, Switzerland), anti-BCL10
(H197, Santa Cruz Biotechnology/Labforce AG, Muttenz, Switzerland),
anti-CARMA1 (1D12, Cell Signaling Technology/Bioconcept), anti-
Tubulin (B-5-1-2, Sigma-Aldrich), anti-Strep-HRP (IBA BioTAGnology/
Lucerna-Chem AG, Luzern, Switzerland). Afﬁnity-puriﬁed antibodies
speciﬁc for MALT1 and cleaved BCL10 have been previously
described.27,34 A monoclonal antibody directed against the Myc
epitope (clone 9E10) was kindly provided by R Iggo (Bordeaux, France).
Horseradish peroxidase–coupled goat anti-mouse (115-035-146) and
anti-rabbit (111-035-144) were from Jackson ImmunoResearch (Milan
Analytica AG, Rheinfelden, Switzerland).
Protein expression vectors
Expression vectors for the 86 myc-tagged ORFs of KSHV in a pcDNA4
background have been previously described.35–37 Point mutants of K13 or
K15 expression constructs were generated by quick-change PCR using
PfuUltra high-ﬁdelity DNA polymerase AD (Agilent Technologies, Morges,
Switzerland) and veriﬁed by sequencing. Tagged MALT1 and BCL10
expression constructs34,38 and the eYFP–Leu-Val-Ser-Arg–eCFP construct39
have been previously described.
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Figure 2. MALT1 inhibition promotes KSHV lytic reactivation. (a and b) RT-PCR analysis of the expression of indicated viral lytic genes in
BCBL-1 and BC-3 cells treated with vehicle or 5 or 10 μM thioridazine (a), or transduced with MALT1 silencing or control vectors (b). MALT1
protein expression was assessed by western blot. Tubulin blot serves as a loading control. (c) Assessment of production of infectious virus
particles by 293 T cells stably transduced with a silencing vector for MALT1 or a control vector, and infected with rKSHV219.33 MALT1 protein
expression in the initial 293 T cell population was monitored by western blot. Tubulin blot serves as a loading control. Data in (a) and (c)
represent means (± s.d.) of two (a) or three (c) independent experiments. Data in (b) represent means± s.d. of triplicate measurements,
representative of two independent experiments. ns: not signiﬁcant; *Po0.05; **Po0.01 (unpaired t-test).
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Transfection and transduction of cells, gene silencing
Transient transfection of HEK293T cells and lentiviral transduction of
HEK293T, BCBL-1 and BC-3 cells were performed using previously
described methods.34,38 For silencing of MALT1 in HEK293T, BCBL-1 and
BC-3 cells, cells were transduced with a lentiviral vector (pAB286.1, a kind
gift of R Iggo, Bordeaux, France) containing short harpin RNA sequences
speciﬁc for BCL10 (5′-GTAGAGAAGACACTGAAGA-3′)38 or MALT1 (5′-GTCA
CAGAATTGAGTGATTTC-3′).40
Cell lysis, immunoprecipitation and immunoblot analysis
Cells were lysed in lysis buffer containing 50 mM HEPES, pH 7.5, 150 mM NaCl,
1% Triton X-100, protease inhibitors (Complete; Roche Diagnostics) and
phosphatase inhibitors (NaF, Na4P2O7 and Na3VO4). For immunoprecipitation,
lysates were precleared for 60 min with Sepharose 6B beads
(Sigma-Aldrich). StrepTactin Sepharose beads (IBA) were then added to
cleared lysates, followed by incubation for 2 h at 4 °C. Beads were washed ﬁve
times with Triton 1% lysis buffer. Samples were boiled in reducing sodium
dodecyl sulfate sample buffer, separated by sodium dodecyl sulfate-polyacryl
amide gel electrophoresis and analyzed by immunoblot as described.34
NF-κB luciferase reporter assay
Activation of gene transcription was assessed by transient transfection of
HEK293T cells with a NF-κB ﬁreﬂy luciferase reporter construct together
with a Renilla luciferase vector (phRL-TK). Cells were lysed in passive lysis
buffer (Promega) and luciferase activity assessed using dual luciferase
assay (Promega) on a TD-20/20 luminometer (Turner Design, Fisher
Scientiﬁc, Reinach, Switzerland).
Analysis of MALT1 protease activity by ﬂow cytometry
Forster resonance energy transfer-based determination of MALT1 protease
activity in HEK293T cells was essentially done as described.39 In brief,
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Figure 3. K13 and K15 induce MALT1 protease activity. (a) 293 T cells were transfected with a eYFP-LVSR-eCFP reporter plasmid and the
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HEK293T cells were transfected with the eYFP–Leu-Val-Ser-Arg–eCFP
reporter construct, together with indicated combinations of KSHV ORFs,
MALT1 and BCL10 expression constructs. After 6 h of transfection, cells
were washed and 24 h later resuspended in ﬂow cytometry buffer
(2% fetal bovine serum in phosphate-buffered saline) and analyzed with an
LSR II ﬂow cytometer (BD Biosciences, Allschwil, Switzerland) containing
405-, 488-, 561- and 640-nm lasers. To measure the eCFP and Forster
resonance energy transfer signal, the transfected cells were excited with a
standard 450/50 ﬁlter for collection of the eCFP ﬂuorescence and a 585/42
ﬁlter for Forster resonance energy transfer ﬂuorescence, respectively, and
for each sample at least 10 000 highly eYFP+ cells were counted.
PEL xenograft model
Aliquots of 107 BCBL-1 cells were diluted in 200 μL sterile phosphate-buffered
saline, and 6–8 week-old male non-obese diabetic/severe-combined immu-
nodeﬁciency mice (Jackson Laboratory, Bar Harbor, ME, USA) received
intraperitoneal injections with a single-cell aliquot. The MALT1 inhibitors
mepazine or thioridazine (10 mg/kg body weight, respectively), or vehicle
alone, was administered using an insulin syringe for intraperitoneal injection.
Drug was administered either 24 h or 28 days (allowed to establish tumor
expansion) after BCBL-1 injection, 3 times/week. Two experiments, with six
mice per group for each experiment, were performed. The PEL expansion
in vivo was conﬁrmed by testing the expression of cell-surface markers
including CD45, CD138, EMA and intranuclear expression of the viral protein
LANA within ascites tumor cells, using IFA and ﬂow cytometry as described
previously.41 Weights were recorded weekly as a surrogate measure of tumor
progression, and ascites ﬂuid volumes were tabulated for individual mice at
the completion of each experiment. Spleen sections were stained by
hematoxylin and eosin for identiﬁcation of tumors inﬁltrating along vascular
channels. Images were collected at ×400 magniﬁcation using a Olympus
BX61 microscope equipped with a high resolution DP72 camera and
CellSense image capture software. All protocols were approved by the
Louisiana State University Health Science Center Animal Care and Use
Committee in accordance with national guidelines (IACUC, No. 3237).
Image quantiﬁcation and statistical analysis
Quantiﬁcation of the relative proportion of monoubiquinated MALT1 in
different samples was performed using ImageJ, and signal intensity of
monoubiquitinated MALT1 was normalized to the band corresponding to
unmodiﬁed MALT1. Two-tailed Student's t-test was used for statistical analysis.
RESULTS
MALT1 activity is required for survival of PEL cell lines
An attractive target for the treatment of ABC DLBCL with chronic BCR
signaling is BTK, a kinase that acts downstream of the BCR and
upstream of the CBM complex.29 To assess if the survival of PEL cells
depends on BTK activity, we treated PEL cell lines BC-3 and BCBL-1
with the BTK inhibitor ibrutinib. As controls, we used HBL-1 cells,
which are derived from DLBCL of the ABC type and characterized by
constitutive BCR signaling, and BJAB cells, which are derived from
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DLBCL of the GCB subtype in which BCR signaling is not activated.29
As expected, ibrutinib induced cytotoxicity in HBL-1 cells, but not in
BJAB cells. Interestingly, both PEL cell lines were insensitive to BTK
inhibition (Figure 1a), and did not express detectable levels of BTK
(Figure 1b), whereas BTK expression was easily detectable in the
cell lines derived from ABC and GCB DLBCL. Similar results were
obtained with two additional PEL cell lines (BC-1 and BCP-1)
(Supplementary Figure 1).
Next, we tested whether the CBM complex, and in particular
MALT1 activity, might be relevant for PEL cell survival, by treating
PEL cell lines with the MALT1 protease inhibitor thioridazine.30
As expected, MALT1 inhibition led to a clear decrease in cell
viability in HBL-1 cells, but did not affect viability of BJAB cells. In
addition, the MALT1 inhibitor was cytotoxic for four independent
PEL cell lines (Figure 1a, Supplementary Figure 1C). Treatment
with the tyrosine kinase inhibitor staurosporine, on the other
hand, induced similar cytotoxicity in all lymphoma cell lines
tested (Figure 1a and Supplementary Figure 1D). The thioridazine-
induced reduction in cell viability correlated with a dose-dependent
induction of apopototic cell death and caspase-3 processing
(Supplementary Figure 1E, see also Supplementary Figure 6C).
Next, we assessed the status of MALT1 expression and activity
in the PEL cell lines BC-3 and BCBL-1. Compared with BJAB and
HBL-1 cells, PEL cell lines expressed slightly lower levels of MALT1
(Figure 1c and Supplementary Figure 2A). The MALT1-binding
protein BCL10 was expressed to similar levels in all lymphoma cell
lines tested, but showed a slightly retarded migration pattern in
BCBL-1 cells (Figure 1c). MALT1 activity, which can be monitored
by the cleavage of BCL10 and by MALT1 autoprocessing,34,42 was
clearly detectable in HBL-1 cells but also, to a lower degree, in the
PEL cell lines BC-3 and BCBL-1 (Figure 1c and Supplementary
Figure 2B). Treatment with the MALT1 inhibitor thioridazine
impaired both BCL10 cleavage and autoprocessing in BCBL-1 cells
(Supplementary Figure 2C). We also found evidence for a weak
K13-Myc
+Mock
_
_
_ +
_
_
_
+
_
_
_
+
_
_
_
+ +
+
+_
_
_ _
Myc
STREP
Myc
Tubulin
95-
72-
55-
43-
34-
26-
55-
26-
26-
Input
STREP-
precipitate
STREP-MALT1
STREP-BCL10
K15-Myc
STREP-MALT1
STREP-BCL10
+Mock
_
_
_ +
_
_
_
+
_
_
_
+
_
_
_
+ +
+
+_
_
_ _
Myc
STREP
Myc
Tubulin
95-
72-
55-
43-
34-
26-
55-
26-
Input
STREP-
precipitate
34-
26-
34-
Tubulin
Myc
STREP
Myc26-
55-
Mock
STREP-MALT1 PD
+
_
+K13-myc _
_
_
+
_
STREP-
precipitate
Input
26-
34-
26-
*
Myc
Myc26-
26-
95-
Mock
STREP-MALT1 WT
STREP-MALT1 DD-Ig1
STREP-MALT1 DD-Ig1/Ig2
+
_
_
_
+K13-myc _
_
_
_
_
+
+
_
_
_
+
+
_
_
_
+
+
_
_
_
72-
55-
STREP-
precipitate
Input
STREP
Tubulin55-
+
MALT1 WT:
MALT1 DD-Ig1:
MALT1 DD-Ig1/Ig2:
MALT1 PD: 
DD Ig1 Ig2 Ig3PD
Ig2 Ig3PD
Ig3PD
PD
Figure 5. K13 but not K15 physically interacts with MALT1. (a) 293 T cells were co-transfected with the indicated combinations of tagged
expression constructs for MALT1 and BCL10, K13 or K15, and protein expression and binding of K13 or K15 to precipitated MALT1 or BCL10
was monitored by western blot. (b) Schematic representation of different MALT1 constructs used to map the MALT1-K13 interaction (ΔDD-Ig1,
deleted of the DD and ﬁrst Ig; ΔDD-Ig1/Ig2, deleted of the DD and ﬁrst two Ig domains; PD, protease domain alone). (c) 293 T cells were
co-transfected with the indicated combinations of tagged expression constructs for K13 and MALT1 (ΔDD-Ig; ΔDD-Ig1/Ig2; PD), and protein
expression and binding of K13 to precipitated MALT1 constructs was monitored by western blot. Tubulin expression serves as a loading
control. Three isoforms are detected for Myc-tagged K15, as previously described.16 Asterisk indicates a non-speciﬁc band detected by
anti-Myc. Data in all ﬁgure panels are representative of two independent experiments.
MALT1 controls growth of primary effusion lymphoma
L Bonsignore et al
619
Leukemia (2017) 614 – 624
constitutive cleavage of A20, corresponding to previously
described bands of ~ 65, 55 and 43 kD23,27 that are detectable
with various intensities in the PEL cell lines (Supplementary
Figure 2D). Surprisingly, the PEL cell lines did not express CARMA1,
a scaffold protein that is essential for antigen receptor-induced
MALT1 activation43,44 (Figure 1c and Supplementary Figure 2A).
We also did not detect expression of the CARMA1 homologs
CARMA3 (CARD10) and CARD9 (data not shown). Collectively, this
suggests that MALT1 activity is essential for the survival of PEL
cells, and that MALT1 activation in PEL cells must occur
independently of BCR-BTK-CARMA1 signaling.
Inhibition of MALT1 activity promotes KSHV reactivation in PEL cell
lines
To assess the mechanism underlying PEL cell death upon MALT1
inhibition with thioridazine (Figure 1a), we next monitored the
expression of viral lytic genes in the two PEL cell lines BCBL-1 and
BC-3. Upon inhibition of MALT1, we observed an increase in the
mRNA expression of viral lytic genes such as ORF57 (MTA), gB and
K8.1 in two PEL cell lines (Figure 2a). An even stronger effect was
obtained upon MALT1 silencing (Figure 2b), which affects both the
scaffold and the catalytic function of MALT1. MALT1 silencing also
favored the upregulation of the lytic KSHV program and release of
infectious virus particles from 293 T cells infected with a previously
described recombinant KSHV33 (Figure 2c). Thus, MALT1 is
constitutively active in PEL cell lines, and inhibition of MALT1
activity compromizes viral latency and leads to lytic reactivation of
KSHV, which speciﬁcally drives PEL cell death.
The latency-associated viral genes K13 and K15 promote MALT1
protease activity
To identify the mechanisms by which KSHV activates MALT1 in
latently infected PEL cells, we screened a validated expression
library of 86 ORFs encoded by KSHV35–37 for their capacity to
induce MALT1 protease activity upon co-expression in 293 T cells.
For this screen, we made use of a previously established, Forster
resonance energy transfer-based reporter assay for MALT1 activity,
which is based on the MALT1-dependent cleavage of an eYFP-
LVSR-eCFP reporter construct that can be monitored by ﬂow
cytometry39 (Supplementary Figure 3). Among the most potent
KSHV genes that increased MALT1 activity were the KSHV-speciﬁc
genes K13 and K15 (Supplementary Figure 3), which are known as
NF-κB-inducing proteins expressed during viral latency45
(Supplementary Figure 4). When tested individually, both K13
and K15 promoted MALT1 activation in a dose-dependent
manner, as evident from reporter cleavage and induction of
MALT1 autoprocessing, which is a consequence of MALT1
activation42 (Figure 3a). K15-induced MALT1 activation was
abolished by mutation of Y481 (Figure 3a), a tyrosine residue that
is part of an SH2-binding motif required for K15-mediated NF-κB
activation12 (Supplementary Figure 5A). In contrast, mutation of a
previously reported TRAF2/3-binding site in K13, which is also
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important for NF-kappa-B essential modulator binding,46 did not
affect the capacity of K13 to activate MALT1 (Supplementary
Figure 5B). In activated lymphocytes, optimal MALT1 activation
requires its monoubiquitination on K644.39 Monoubiquinated
MALT1 is stabilized and thus more easily detectable under
conditions of catalytic inactivation of MALT1, possibly because
of reduced autoprocessing and/or turnover of the active form of
MALT1.39,42 As previously described, co-expression of a catalyti-
cally inactive C464A mutant of MALT1 with BCL10 in 293 T cells
led to MALT1 monoubiquitination, which can be monitored by the
appearance of a slower migrating form of MALT1(ref.39) (Figure 3b).
Monoubiquitination of MALT1 was further increased by co-
expression of K13 or K15 (Figure 3b). K15-induced monoubiqui-
tination of MALT1 was greatly impaired by mutation of Y481
(Figure 3b), consistent with the requirement of Y481 for MALT1
activation (Figure 3a). Collectively, these ﬁndings suggest that
both KSHV proteins K13 and K15 can induce MALT1 protease
activity by promoting the monoubiquitination-dependent activa-
tion of MALT1.
K13 and K15-dependent NF-κB activation is impaired upon MALT1
silencing
Next, we tested whether K13 and K15 promote NF-κB gene
transcription via MALT1 and possibly via its binding partner BCL10
that is required for MALT1 activation in lymphocytes.34 Silencing
of MALT1 (Figure 4a) or BCL10 (Figure 4b) partially affected both
K13- and K15-induced NF-κB activation. Moreover, K13- or K15-
induced NF-κB activation was strongly increased by co-expression
of wild-type MALT1, but much less so by the catalytically inactive
C464A mutant of MALT1 (Supplementary Figure 6). In addition, we
have assessed the effect of the MALT1 inhibitor thioridazine on
the expression of the NF-κB target genes cFLIP and c-IAP1, and
found that MALT1 inhibition led to a reduced expression of these
target genes and a correlating increase in caspase-3 activation
(Supplementary Figure 6C). K13 most likely promoted NF-κB
activation by direct or indirect physical recruitment of MALT1,
as K13 interacted with MALT1 but not with BCL10 upon
co-expression of the proteins in 293 T cells (Figure 5a). Under
similar conditions, no physical interaction of K15 with MALT1 or
BCL10 was detectable (Figure 5a). Using various MALT1 constructs
deleted in individual domains (Figure 5b), we then mapped the
region of MALT1 that interacted with K13. This revealed that
the DD and the two N-terminal Ig domains of MALT1 were not
necessary for the interaction, whereas the protease domain was
both required and sufﬁcient for the interaction with K13
(Figure 5c). Thus, K13 probably activates MALT1 and consequently
NF-κB via binding to its protease domain, either directly or via an
additional binding partner. K15 most likely activates MALT1
indirectly, via the Y481-dependent recruitment of additional
signaling proteins.
MALT1 inhibitors prevent the growth of PEL in a xenograft model
To test whether MALT1 inhibition could be of interest for
the treatment of PEL, we subsequently assessed the effect
of two small molecule inhibitors of MALT1 on the growth of
BCBL-1 cells in a xenograft model.41 BCBL-1 cells were injected
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intraperitoneally into non-obese diabetic/severe-combined immu-
nodeﬁciency mice, and 24 h later, we started treatment of the
mice with a 3 times per week intraperitoneal injection of the
MALT1 inhibitors mepazine or thioridazine30 (both at 10 mg/kg)
for 4 weeks. Establishment of PEL was monitored by measuring
tumor-related gain in body weight, spleen size and ascites volume
at the indicated time points (Figure 6a). Compared with mice
treated with vehicle alone, mepazine- or thioridazine-treated mice
showed an almost complete inhibition of tumor-related gain in
body weight and spleen enlargement (Figures 6b and c), and of
ascites formation (Figure 6c) measured after 4 weeks of treatment.
Hematoxylin and eosin staining enabled us to observe a great
amount of tumor inﬁltration into the spleen of vehicle-treated
mice, whereas only small tumor nodules were dispersed in the
spleen of mepazine- or thioridazine-treated mice (Supplementary
Figure 7). Thus, MALT1 inhibition is highly efﬁcient in preventing
the development of xenografted PEL in vivo.
MALT1 inhibitors efﬁciently induces regression of established PEL
tumors in vivo
Next, we assessed whether MALT1 inhibition was also efﬁcient in
mice with already established PEL. To test this, mice were
inoculated with BCBL-1 cells at day 0, and treatment with vehicle,
mepazine or thioridazine was initiated only after 28 days, when
the mice had already well established PEL. Tumor-related gain in
body weight, spleen size and ascites volume were monitored at
the indicated time points (Figure 7a). Compared with mice treated
with vehicle only, mepazine- or thioridazine-treated animals
showed a signiﬁcant regression of tumor-related spleen enlarge-
ment and gain in body weight (Figures 7b and c), and a complete
loss of measurable ascites volume (Figure 7c) upon 21 days of
treatment. Therefore, we conclude that MALT1 inhibition by
mepazine or thioridazine is highly efﬁcient not only in preventing
the establishment of PEL expansion, but also in promoting the
regression of established PEL in this xenograft model.
DISCUSSION
In this study, we provide several lines of evidence for an essential
role of the paracaspase MALT1 in the malignant growth of latently
KSHV-infected PEL cells. First, we found that MALT1 was
constitutively active in PEL cell lines in the absence of BCR/BTK/
CARMA1 signaling. Second, MALT1 inhibition with a small
molecule inhibitor induced the viral lytic program and impaired
cell viability. Third, we showed that MALT1 expression and activity
contributes to K13- and K15-driven NF-κB activation, which
controls the growth and survival of latently KSHV-infected B cells
and development of PEL. Finally, MALT1 inhibition prevented the
development of xenografted PEL in vivo, and led to efﬁcient
regression of established PEL in this xenograft model. Collectively,
these ﬁndings identify MALT1 as a key driver of KSHV latency, and
as a potentially interesting target for the treatment of PEL
(Figure 8).
Among the latent KSHV genes previously demonstrated to have
a capacity to activate NF-κB, K13 and K15 were able to potently
promote MALT1 activation. K13 directly or indirectly interacted
with MALT1 and in particular its protease domain, and may thus
induce a conformational change in the protease domain that
promotes MALT1 activation, for example, by rendering it
accessible to monoubiquitination. The transmembrane protein
K15 seemed to use a distinct mechanism that required Y481 in its
cytoplasmic SH2-binding motif, and thus most likely mediates
MALT1 activation by the recruitment of an SH2 domain-containing
protein that remains to be identiﬁed (Figure 8). Both K13 and K15
have previously been described to activate NF-κB via IKK
components,17–19 and MALT1 has been proposed to physically
recruit and activate the IKK complex.20,47 Whether MALT1 and IKK
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components are part of the same or distinct K13-/K15-induced
signaling complexes, and whether IKK- and MALT1-dependent
NF-κB activation by K13 and K15 happens in a simultaneous or
sequential manner will have to be investigated in future studies.
Several different types of lymphomas are driven by oncogenic
activation of the NF-κB pathway; signaling components driving
NF-κB activation in tumor cells have thus gained attention as
rational drug targets in lymphomas.29 A lymphoma type with
constitutive MALT1-dependent NF-κB activation is the ABC DLBCL,
in which MALT1 is activated by chronic BCR-BTK-CARMA1
signaling.29 The majority of ABC DLBCL cell lines therefore
respond to inhibition of BCR signaling by the BTK inhibitor
ibrutinib.29 In contrast, PEL cell lines lack signiﬁcant surface BCR
expression,48 and are resistant to treatment with Dasatinib, which
inhibits upstream tyrosine kinase activity.49 This suggests that
NF-κB activation in PEL does not rely on early BCR-signaling
events, but rather on K13- and K15-mediated NF-κB activation
that occurs in a BTK- and CARMA1-independent, but MALT1- and
IKK-dependent manner. Inhibition of NF-κB activation by the
IKK inhibitor Bay-11-7082 efﬁciently inhibits the development of
xenografted PEL in vivo.9 Drugs targeting IKK-dependent NF-κB
activation directly (such as IKK inhibitors) or indirectly (such as
proteasome inhibitors) are under development or used in
preclinical trials for PEL treatment,9,50 but adverse side-effects
of these drugs due to systemic NF-κB inhibition in all cell types
and/or NF-κB independent effects of proteasome inhibitors
remain a concern.51,52 MALT1 activity, which appears to be
important mainly for immune cells,53–56 might thus be a rational
alternative target for the treatment of PEL. Possible adverse
side-effects of long-term MALT1 inhibition include compromized
regulatory T cells responses and autoimmunity as MALT1 is
required during embryonic development for the generation of
regulatory T cells.53–56 However, such side-effects have thus far
not been reported during short-term treatments with MALT1
inhibitors. Our data using PEL cell lines and a xenograft model
suggest that MALT1 inhibition may be efﬁcient in purging
the reservoir of latently infected PEL cells, promoting viral lytic
replication. Therapeutic MALT1 inhibition should thus be
combined with an anti-herpes virus drug that limits viral
replication and spreading, such as the nucleoside analog
ganciclovir.5,57
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